ArticleIJU case reports2025
Recurrence of seminoma 48 years after orchiectomy: Longest late recurrence and treatment.
Article in IJU case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although not frequent, the recurrence of seminoma later than 5-10 years after orchiectomy has been reported. We report a case of recurrence of seminoma 48 years after orchiectomy, with metastasis to the para-aorta that was treated with chemotherapy. Case presentation: An 83-year-old man had an incidentally enlarged para-aortic lymph node noted on computed tomography. Needle biopsy revealed metastasis from a seminoma that had been treated with orchiectomy at age 35. Chemotherapy was introduced but discontinued after the first course due to side effects. However, a decrease in fluorodeoxyglucose accumulation on positron emission tomography was observed, with no subsequent re-enlargement of the tumor. Conclusion: Chemotherapy was introduced for an elderly patient with the longest known late relapse. Dose reduction should be considered in cases with good prognosis, considering factors such as age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.